Methadone, Pierre Robin sequence and other congenital anomalies: case-control study.


Journal

Archives of disease in childhood. Fetal and neonatal edition
ISSN: 1468-2052
Titre abrégé: Arch Dis Child Fetal Neonatal Ed
Pays: England
ID NLM: 9501297

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 06 01 2019
revised: 11 05 2019
accepted: 14 05 2019
pubmed: 24 6 2019
medline: 10 3 2020
entrez: 24 6 2019
Statut: ppublish

Résumé

Methadone is a vital treatment for women with opioid use disorder in pregnancy. Previous reports suggested an association between methadone exposure and Pierre Robin sequence (PRS), a rare craniofacial anomaly. We assessed the association between gestational methadone exposure and PRS. This case-malformed control study used European Surveillance of Congenital Anomalies population-based registries in Ireland, the Netherlands, Italy, Switzerland, Croatia, Malta, Portugal, Germany, Wales, Norway and Spain, 1995-2011. Cases included PRS based on International Classification of Disease (ICD), Ninth Edition-British Paediatric Association (BPA) code 75 603 or ICD, Tenth Edition-BPA code Q8708. Malformed controls were all non-PRS anomalies, excluding genetic conditions, among live births, fetal deaths from 20 weeks' gestation and terminations of pregnancy for fetal anomalies. An exploratory analysis assessed the association between methadone exposure and other congenital anomalies (CAs) excluding PRS. Methadone exposure was ascertained from medical records and maternal interview. Among 87 979 CA registrations, there were 127 methadone-exposed pregnancies and 336 PRS cases. There was an association between methadone exposure and PRS (OR adjusted for registry 12.3, 95% CI 5.7 to 26.8). In absolute terms, this association reflects a risk increase from approximately 1-12 cases per 10 000 births. A raised OR was found for cleft palate (adjusted OR 5.0, 95% CI 2.7 to 9.2). These findings suggest that gestational methadone exposure is associated with PRS. The association may be explained by unmeasured confounding factors. The small increased risk of PRS in itself does not alter the risk-benefit balance for gestational methadone use. The association with cleft palate, a more common CA, should be assessed with independent data.

Identifiants

pubmed: 31229957
pii: archdischild-2019-316804
doi: 10.1136/archdischild-2019-316804
doi:

Substances chimiques

Methadone UC6VBE7V1Z

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-157

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Brian Cleary (B)

Pharmacy Department, Rotunda Hospital, Dublin, Ireland.
School of Pharmacy, Royal College of Surgeons in Ireland, Dublin, Ireland.

Maria Loane (M)

Centre for Maternal, Fetal and Infant Research, INHR, Ulster University, Newtowanbbey, UK.

Marie-Claude Addor (MC)

Division Autonome de Genetique Medicale, Registre Vaudois des Malformations, Vaud, Switzerland.

Ingeborg Barisic (I)

Children's Hospital Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.

Hermien E K de Walle (HEK)

Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Carlos Matias Dias (C)

Centro de Estudos e registo de A C, Lisbon, Portugal.

Miriam Gatt (M)

Department of Health Information, Malta Congenital Anomalies Registry, G'mangia, Malta.

Kari Klungsoyr (K)

Medical Birth Register of Norway, Nasjonalt folkehelseinstitutt, Oslo, Norway.

Bob McDonnell (B)

Health Service Executive, Dublin, Ireland.

Amanda Neville (A)

Azienda Ospedaliero - Universitaria di Ferrara, Registro IMER, Ferrara, Italy.

Anna Pierini (A)

Istituto di Fisiologia Clinica CNR, Pisa, Italy.

Anke Rissmann (A)

Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty Otto-von-Guericke University, Magdeburg, Germany.

David F Tucker (DF)

Congenital Anomaly Register and Information Service for Wales, Public Health Wales, Swansea, UK.

Oscar Zurriaga (O)

Centro Superior de Investigación en Salud Pública, Valencia, Spain.
Direccion General de Investigación y Salud Pública, Valencia, Spain.

Helen Dolk (H)

University of Ulster, Jordanstown, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH